Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU’s New Health Threats Body Could Speed Arrival Of New Antibiotics

‘Pull’ Incentives Will Be Vital In Spurring Drug Development

Executive Summary

Europe is preparing a “preparatory action” to review existing measures for tackling antimicrobial resistance, identify the gaps, and to determine what products will be needed in future.

You may also be interested in...



EMA Aligns Antibiotics Guideline To Help Facilitate Global Trials

The EU regulator says it supports a globally aligned approach to the development of new antimicrobial medicines.

European Industry Proposes Incentive To Develop New Antimicrobials

With proposals for an overhaul of the EU medicines legislation due at the end of this year, EFPIA has published its formal response to the European Commission’s consultation with suggestions for facilitating new antibiotic development, testing new regulatory approaches to novel medicines, and tackling medicine shortages.

EU Launches New Response Body To Tackle Future Health Emergencies

The European Commission has dismissed concerns about the operation of its new emergency response body, saying it will ensure the EU is well prepared for tackling future pandemics and other threats. HERA will complement, not duplicate, work conducted by existing agencies such as the European Medicines Agency, delegates heard at this week’s European Health Forum Gastein virtual conference.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel